John Kaiser finds next CEO role at Duke spin­out Evecx­ia; Im­muno­core vet Namir Has­san moves to I/O biotech Zel­lu­na

→ Duke spin­out Evecx­ia has re­cruit­ed bio­phar­ma vet John Kaiser to steer clin­i­cal and busi­ness plans for its 5-hy­drox­ytryp­to­phan slow-re­lease de­pres­sion treat­ment. This will be his third time in a CEO role. Af­ter leav­ing a 28-year sales and mar­ket­ing ca­reer at Eli Lil­ly, Kaiser found­ed and ran a now-de­funct biotech, then had a stint as in­ter­im CEO at Cere­cor, where he had or­ches­trat­ed sev­er­al li­cens­ing deals as chief busi­ness of­fi­cer (Cere­cor is al­so de­vel­op­ing, among oth­er things, a de­pres­sion drug). Evecx­ia is now in the clin­ic with EVX-101, a first-line ad­junc­tive treat­ment for de­pressed pa­tients re­spond­ing in­ad­e­quate­ly to con­ven­tion­al an­ti­de­pres­sants, though it’s un­clear ex­act­ly what stage they are in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER